TARGETS UNDER SCOPE FLUIDICS GROUP STRATEGY UNTIL 2027

Adopted in March 2023, the Scope Fluidics Group Strategy (the "**Strategy**") establishes the following three growth objectives for the Group (the "**Strategic Objectives**"):

- By the end of 2025, to add at least five new projects to the portfolio, including at least two structured as special purpose vehicles – this was successfully achieved in early 2025.
- By the end of 2028, to complete at least two strategic transactions.
- Over 2029–2033, to be positioned to execute, on average, at least one strategic transaction per year.

The ability to deliver the Strategic Objectives depends on a range of internal factors – such as the quality of available talent, applied methodologies, and the effectiveness of operational decision-making – and external factors, encompassing life sciences M&A sentiment, transaction trends, and capital market access. These variables collectively determine resource availability for optimal and timely project implementation and execution of any associated divestiture processes.

As at 31 December 2024, the Scope Fluidics Group (the "**Group**") held cash and cash equivalents of approximately PLN 150 million, including PLN 60 million subject to potential shareholder distribution by the General Meeting from 2024 net profit. Given current macroeconomic uncertainty and volatile capital market sentiment, the Management Board has resolved to recommended that the Annual General Meeting vote to retain approximately PLN 84 million of unappropriated net profit, following satisfaction of the statutory requirements under the Commercial Companies Code for loss coverage and reserve funds (see Current Report No. 7/2025). The Management Board believes that while the AGM's decision consistent with the Management Board's recommendation would enable the Group to gradually develop its projects until 30 June 2027, it would on its own fail to provide sufficient resources to unlock the full value-creation potential of the Group's existing projects (BACTEROMIC, EDOCERA, HYBOLIC) or support the origination of new projects for development within dedicated SPVs.

Recognising the commercial potential of the Group's project portfolio and aiming to ensure value creation for the Group, the Management Board of Scope Fluidics S.A. ("**Scope**") adopted the "Targets under the Scope Fluidics Group Strategy until 2027" (the "**Targets**"). These Targets encompass intensified development of the three core subsidiary projects, i.e., BACTEROMIC, EDOCERA and HYBOLIC, as well as the strengthening and further development of Scope Discovery capabilities and establishing additional SPVs. In the Management Board's opinion, achievement of these Targets will enhance the Group's negotiating position for any Strategic Transaction (as defined in the Strategy) involving the BACTEROMIC system, optimise value realisation from the BACTEROMIC project, accelerate development timelines for EDOCERA and HYBOLIC, and enable creation of two to three additional SPVs with dedicated project development programmes.

SCOPE DISCOVERY

Achievement of the Targets will enable Scope Discovery to designate two to three additional projects for special SPV development during the 2025 to 2027 period. This expansion will bring the Group's total portfolio of subsidiaries originating from the Scope Discovery process to four or five entities by the end of 2027.

EDOCERA

The EDOCERA project, developed by subsidiary Edocera sp. z o.o., will benefit from significantly accelerated development timelines resulting from delivery of the Targets. The review for selected technologies is scheduled for completion during the second half of 2025, after which the team will immediately commence prototype development with delivery targeted for 2026. Concurrent with prototype development, the team will begin device software development and throughout 2025 conduct research and testing of specific solutions integral to the EDOCERA product. These foundational activities will conclude in 2027, which will enable commencement of work on the initial version of the device version, which will undergo market validation before proceeding to regulatory clearance and certification processes. Market validation activities will run continuously throughout 2026 and 2027 to ensure commercial readiness.

The development programme also provides for the first patent or utility-model filings in 2027.

HYBOLIC

For the HYBOLIC project, undertaken by subsidiary Hybolic sp. z o.o., delivery of the Targets entails intensive technology development programme encompassing research and development, performance and clinical evaluations, product development, and integration of device components. In 2025, efforts will centre on confirming the efficacy of the selected insulin assay methodology. Development focus will shift in 2026 to integrating selected methods and techniques into a unified sensor-measurement system. In addition, pre-clinical trials in the form of a medical experiment are scheduled for 2026 to validate the hypothesis that insulin measurement can serve diagnostic and predictive applications. Prototype completion is targeted for 2027, followed by development of the commercial target device. By the end of 2027, all key components developed as part of the HYBOLIC project are expected to integrate into a fully functional system, which will position the technology for advanced product development and commercial deployment.

BACTEROMIC

For the BACTEROMIC project, developed through Bacteromic sp. z o.o., the Targets are designed to enhance its valuation to levels the Management Board believes necessary for executing a Strategic Transaction. The Targets address, to the best of the Management Board's knowledge, the principal expectations of potential investors who might be interested in executing a Strategic Transaction to acquire the BACTEROMIC project (the "**Investors**"). Crucially, achievement of the Targets is projected to deliver financial self-sufficiency for BACTEROMIC by 2028, creating, in the Management Board's opinion, a compelling investment incentive for Investors.

R&D

For 2025, the R&D programme encompasses the development of:

- a fast-detection interpreter software capable of identifying bacterial growth and determining antibiotic susceptibility within no more than eight hours;
- the Rapid UNI Panel, an enhanced version of the existing UNI Panel optimised for fast detection, providing antibiotic susceptibility testing for approximately 30 antibiotics with results delivered within no more than eight hours;
- the Rapid BSI (PBC)* Panel, intended for bloodstream-infection diagnostics (Positive Blood Culture, PBC), delivering results within no more than eight hours and covering antibiotics critical for treating the most common bacterial pathogens in bloodstream infections; given the urgency associated with sepsis, this panel will be developed exclusively in a version compatible with fast detection (BSI stands for Blood Stream Infection; depending on the region, BSI or PBC diagnostics is commonly used to refer to bloodstream-infection diagnostics).

2026 will see conclusion of the development work on:

- the UNI MAX Panel, an extension of the UNI Panel that is currently expected to enable assessment of antibiotic susceptibility for around 40 antibiotics and detection of one ESBL resistance mechanism; and
- the Rapid UNI MAX Panel, i.e. the UNI MAX Panel operating with fast detection software.

In parallel, ongoing optimisation of the analyser and the filling unit will continue.

The Company further notes that commercial considerations may necessitate adjustments to the specific antibiotic compositions within individual panels or modifications to development work sequencing as the programme progresses.

Clearance/certification

The Company remains committed to securing IVDR conformity certification (the "**IVDR Certificate**") for the BACTEROMIC system operating with the UNI Panel and current interpreter software by the end of 2025. Performance evaluations of the system are currently underway in collaboration with a contract research organisation (CRO), with results required for a submission to the Notified Body to complete the IVDR certification process. At present, Bacteromic does not yet have results ready to present to the Notified Body. The first statistically significant results tranche, sufficient for preliminary performance assessment of the BACTEROMIC system, is expected within the coming weeks. Given the nature of R&D activities, particularly for innovative products, no assurance can be given that the results will not indicate a need to modify certain elements of the BACTEROMIC system and to seek re-evaluation; however, this is not the scenario currently anticipated.

In 2026, the Company plans to obtain an IVDR Certificate for the BACTEROMIC system with the following panel configurations: Rapid UNI, Rapid BSI, and UNI MAX. IVDR certification for the Rapid UNI MAX Panel will follow in 2027. For 2027, the Company also targets receiving FDA clearance of the BACTEROMIC system with two panel configurations: the Rapid UNI Panel and the Rapid BSI Panel. Certification/clearance timelines remain contingent on progress in developing the new panels and the fast-detection software.

Production capacity and panel manufacturing

To secure panel production capacity, Bacteromic has established a collaboration with TE Connectivity plc ("**TE**"), a member of the TE Connectivity Group. TE is currently developing a semi-automated production line with a capacity of 750,000 panels, which will enable commercial manufacture of panels for the BACTEROMIC system (the "**Production Line**"). This production line is scheduled for commissioning by the end of 2025. The Targets also provide for more than doubling this production capacity during 2027, together with preparatory work to enable a subsequent doubling thereafter.

Device manufacturing, encompassing both the analyser and filling unit, is currently undertaken through partnership with BIT Analytical Instruments GmbH ("**BIT**"). In parallel, following developments at BIT as disclosed in Current Report No. 13/2025, the Company is actively engaging alternative suppliers to ensure continuity of device supply in the future.

Organic sales of the BACTEROMIC system

The market entry of the BACTEROMIC system is planned in collaboration with local distributors across target geographies. The Bacteromic team is implementing a comprehensive business partnership development strategy with a view to selecting distributors, including providing the system to prospective partners for review and evaluation (currently on an R&D use only basis), conducting structured negotiations to establish collaboration frameworks, and execution of pilot trials and usability studies.

The phased market entry strategy targets initial expansion into selected Central and Eastern European markets, excluding Poland, and Middle Eastern countries by the end of 2026. The second phase, scheduled for completion by the end of 2027, encompasses market entry in the United Kingdom, selected Western European countries, and the United States. These geographic priorities are merely illustrative of the Company's preferences rather than any definitive commitments. The above BACTEROMIC commercial deployment plan reflects the Company's current intentions and may evolve as implementation progresses, particularly in response to future geopolitical and macroeconomic conditions. Initial commercial sales are anticipated during 2026.

In 2026–2027, Bacteromic is projected to generate approximately PLN 30 million in revenue.

CAPEX AND FINANCING

Achievement of the Targets for 2025–2027 will require total CAPEX of PLN 240 million, which includes outlays already incurred since 1 January 2025. The investment allocation prioritises value maximisation for the BACTEROMIC project, which will receive more than half of the total capital commitment. Approximately one third of the funding will substantially enhance development capacity for the remaining projects and Scope Discovery operations, whilst the balance will support essential corporate activities required for effective Group operations. No assurance can be given that, , as implementation progresses, there will be no upwards or downward variations in expenditure from these projections, or that funds will not be reallocated between specific years or project components.

Subject to retention of Scope's entire 2024 net profit within the Group, delivery of the Targets would be substantially financed using internal resources totalling approximately PLN 185 million. This figure comprises the PLN 150 million cash position as at 31 December 2024, including 2024 earnings and finance income, plus projected revenue of approximately PLN 35 million. The Group will secure additional financing of PLN 55 million to complete the funding requirements.

Absent additional financing, the Group would maintain the capacity to gradually develop its projects until 30 June 2027 but would be unable to realise the full value-creation potential of the projects already underway within the Group (BACTEROMIC, EDOCERA, HYBOLIC) or support the origination of new projects for development within dedicated SPVs.

This constrained funding scenario would limit establishment of new special purpose vehicles to two entities operating under significantly reduced budgets, rather than the targeted three vehicles, whilst substantially decelerating development timelines across all subsidiaries emerging from the Scope Discovery process. The BACTEROMIC project would face three specific limitations: (i) inability to pursue one of the two FDA clearances, namely for the Rapid PBC Panel; (ii) restricted organic sales activities resulting in diminished market recognition and limited market validation opportunities; and (iii) inability to scale cartridge manufacturing to achieve optimal unit cost reductions. Importantly, under this scenario, Bacteromic's path to financial self-sufficiency would extend beyond current projections, which could potentially affect both the timing and terms of any Strategic Transaction and necessitate raising additional capital.

Consistent with its established business model, the Company maintains an active approach to securing additional financing through diverse channels, including debt facilities and grant funding opportunities. Given prevailing market conditions and macroeconomic uncertainties, and to ensure successful delivery of the Targets, the Management Board believes it prudent to enhance financing structure flexibility by enabling capital raising up to the authorised capital limit as a long-term growth funding mechanism. Expanding the Company's capital raising capabilities to support accelerated and comprehensive development of the Group's project portfolio, particularly the flagship BACTEROMIC project, serves the interests of both existing and prospective shareholders.

The Management Board further considers that maintaining accessible equity funding capacity through potential share issuance will strengthen Scope's negotiating position in any Strategic Transaction involving the BACTEROMIC system. This enhanced financial flexibility materially reduces liquidity constraints that potential Investors might otherwise leverage to extend negotiation timelines or defer transaction completion.

The Management Board considers it both reasonable and advisable to secure authority for increasing the Company's share capital up to the authorised capital limit through issuance of one or more series of bearer shares, with full disapplication of existing shareholders' pre-emptive rights. Granting such authority does not automatically entail that the Management Board will exercise it, in whole or in part. Any share capital increase would serve to expand the Company's financing options portfolio, with the authority itself remaining discretionary rather than deterministic of actual implementation.

The Management Board maintains its commitment to identifying optimal financing solutions for delivery of the Targets. Current assessments by the Management Board preclude both definitive commitment to equity raising as the preferred financing route and categorical exclusion of equity as an initial funding mechanism. All financing decisions will prioritise Company and shareholder interests and will take into account prevailing economic conditions and their implications for the execution of the Group's strategies.

Accordingly, the Management Board intends to ask the Annual General Meeting ("**AGM**") to authorise the Management Board to increase the Company's share capital up to the authorised capital limit, with pre-emptive rights disapplied, through issuance of up to 680,000 shares in one or more tranches until 17 June 2028 (the "**Authorisation**"). The Authorisation extends beyond immediate needs arising from the Targets and as such would enable the Management Board's rapid response to market developments and adjusting the Group's growth trajectory. Such flexibility would position the Group to capitalise promptly on favourable macroeconomic or geopolitical shifts, providing additional justification for the disapplication of pre-emptive rights. The proposed Authorisation would also enhance flexibility in pursuing collaboration opportunities with potential strategic and institutional investors. The Management Board considers that maintaining accessible capital raising mechanisms significantly strengthens the Company's negotiating position in structuring such partnerships, particularly where opportunities demand swift execution capability. This operational requirement provides further rationale for the disapplication of pre-emptive rights. The Management Board believes that expanding financing options to the full authorised capital limit, while reducing Group liquidity constraints, will materially strengthen Scope's negotiating position in any Strategic Transaction involving the BACTEROMIC system. The Authorisation could substantially accelerate financing capabilities should new investors, particularly international institutions, express interest in Scope. Relevant draft resolutions, accompanied by detailed explanatory statements, will be published together with the AGM Notice.